Literature DB >> 26003548

Utility of Ultrasound, Transaminases, and Visual Inspection to Assess Nonalcoholic Fatty Liver Disease in Bariatric Surgery Patients.

Anthony Petrick1, Peter Benotti2, G Craig Wood1, Christopher D Still1, William E Strodel1, John Gabrielsen1, David Rolston1, Xin Chu1, George Argyropoulos1, Anna Ibele1, Glenn S Gerhard3.   

Abstract

BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is common in adults with extreme obesity and can impact long-term health and survival. Liver biopsy is the only accurate test for diagnosis and staging, but is invasive and costly. Non-invasive testing offers an attractive alternate, but the overall accuracy remains a significant issue. This study was conducted to determine the accuracy and clinical utility of pre-operative ultrasound and liver transaminase levels, as well as intra-operative hepatic visual inspection, for assessing presence of NAFLD as confirmed by hepatic histology.
METHODS: Data was collected prospectively from 580 morbidly obese adult patients who underwent Roux-en-Y gastric bypass surgery with intraoperative wedge biopsy between January 2004 and February 2009. Complete data for ultrasound, ALT and AST levels, and documented visual inspection was available for 513 patients.
RESULTS: The prevalence of NAFLD was 69 % and that of NASH was 32 %. The individual non-invasive clinical assessments demonstrated low sensitivity, specificity, and accuracy for detecting the presence of steatosis, steatohepatitis, or fibrosis. The combination of normal or abnormal results for all tests improved predictive utility. Abnormal tests with all three assessments had a sensitivity of 95-98 % and a specificity of 28-48 % for major histologic findings in NAFLD/NASH. Normal tests with all three assessments had a sensitivity of 12-22 % and a specificity of 89-97 % for major histologic findings in NAFLD/NASH.
CONCLUSIONS: Although individual clinical tests for NAFLD have limited accuracy, the use of combined clinical tests may prove useful.

Entities:  

Keywords:  Bariatric surgery; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Ultrasound

Mesh:

Substances:

Year:  2015        PMID: 26003548      PMCID: PMC4917009          DOI: 10.1007/s11695-015-1707-6

Source DB:  PubMed          Journal:  Obes Surg        ISSN: 0960-8923            Impact factor:   4.129


  31 in total

1.  Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese.

Authors:  J B Dixon; P S Bhathal; P E O'Brien
Journal:  Gastroenterology       Date:  2001-07       Impact factor: 22.682

2.  Predictors of nonalcoholic steatohepatitis (NASH) in obese patients undergoing gastric bypass.

Authors:  Camilo Boza; Arnoldo Riquelme; Luis Ibañez; Ignacio Duarte; Enrique Norero; Paola Viviani; Alejandro Soza; Jose Ignacio Fernandez; Alejandro Raddatz; Sergio Guzman; Marco Arrese
Journal:  Obes Surg       Date:  2005-09       Impact factor: 4.129

Review 3.  Noninvasive assessment of fibrosis in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

Authors:  Luca Miele; Alessandra Forgione; Giovanni Gasbarrini; Antonio Grieco
Journal:  Transl Res       Date:  2007-03       Impact factor: 7.012

4.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.

Authors:  E M Brunt; C G Janney; A M Di Bisceglie; B A Neuschwander-Tetri; B R Bacon
Journal:  Am J Gastroenterol       Date:  1999-09       Impact factor: 10.864

5.  Body fat topography as an independent predictor of fatty liver.

Authors:  J G Kral; F Schaffner; R N Pierson; J Wang
Journal:  Metabolism       Date:  1993-05       Impact factor: 8.694

6.  Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values.

Authors:  Pouneh Mofrad; Melissa J Contos; Mahmadul Haque; Carol Sargeant; Robert A Fisher; Velimir A Luketic; Richard K Sterling; Mitchell L Shiffman; Richard T Stravitz; Arun J Sanyal
Journal:  Hepatology       Date:  2003-06       Impact factor: 17.425

Review 7.  Overview and developments in noninvasive diagnosis of nonalcoholic fatty liver disease.

Authors:  Neven Baršić; Ivan Lerotić; Lea Smirčić-Duvnjak; Vedran Tomašić; Marko Duvnjak
Journal:  World J Gastroenterol       Date:  2012-08-14       Impact factor: 5.742

8.  The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD.

Authors:  Paul Angulo; Jason M Hui; Giulio Marchesini; Ellisabetta Bugianesi; Jacob George; Geoffrey C Farrell; Felicity Enders; Sushma Saksena; Alastair D Burt; John P Bida; Keith Lindor; Schuyler O Sanderson; Marco Lenzi; Leon A Adams; James Kench; Terry M Therneau; Christopher P Day
Journal:  Hepatology       Date:  2007-04       Impact factor: 17.425

9.  Predictors of nonalcoholic steatohepatitis in patients undergoing bariatric surgery: when is liver biopsy indicated?

Authors:  Thomas S Helling; John H Helzberg; Jagdish S Nachnani; Krishna Gurram
Journal:  Surg Obes Relat Dis       Date:  2008-01-28       Impact factor: 4.734

10.  Noninvasive biomarkers for the diagnosis of steatohepatitis and advanced fibrosis in NAFLD.

Authors:  Steven G Pearce; Nirav C Thosani; Jen-Jung Pan
Journal:  Biomark Res       Date:  2013-02-04
View more
  11 in total

Review 1.  Gastric Bypass and Influence on Improvement of NAFLD.

Authors:  Vamsi Alli; Ann M Rogers
Journal:  Curr Gastroenterol Rep       Date:  2017-06

2.  Safety and Utility of Liver Biopsy During Bariatric Surgery in the New Zealand Setting.

Authors:  Hannah Collins; Grant Beban; John Windsor; Rishi Ram; David Orr; Nicholas Evennett; Benjamin Loveday
Journal:  Obes Surg       Date:  2020-01       Impact factor: 4.129

3.  Utility of the ELF Test for Detecting Steatohepatitis in Morbid Obese Patients with Suspicion of Nonalcoholic Fatty Liver Disease.

Authors:  Iria Cebreiros López; Florentina Guzmán Aroca; Maria Dolores Frutos Bernal; Juan Antonio Luján Mompeán; Águeda Bas Bernal; Antonio Miguel Hernández Martínez; Enrique Martínez Barba; Jose Antonio Noguera Velasco; Pascual Parilla Paricio
Journal:  Obes Surg       Date:  2017-09       Impact factor: 4.129

4.  High False-Negative Rate for Nonalcoholic Steatohepatitis in Extreme Obesity.

Authors:  Glenn S Gerhard; Christopher D Still; Johanna K DiStefano
Journal:  Gastroenterology       Date:  2015-11-23       Impact factor: 22.682

Review 5.  Circulating microRNAs in nonalcoholic fatty liver disease.

Authors:  Johanna K DiStefano; Glenn S Gerhard
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2015-12-15       Impact factor: 3.869

6.  Histopathological examination of tissue resected during bariatric procedures - to be done or not to be done?

Authors:  Maciej Walędziak; Anna Różańska-Walędziak; Piotr K Kowalewski; Michał R Janik; Krzysztof Paśnik
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2017-05-19       Impact factor: 1.195

7.  A multi-component classifier for nonalcoholic fatty liver disease (NAFLD) based on genomic, proteomic, and phenomic data domains.

Authors:  G Craig Wood; Xin Chu; George Argyropoulos; Peter Benotti; David Rolston; Tooraj Mirshahi; Anthony Petrick; John Gabrielson; David J Carey; Johanna K DiStefano; Christopher D Still; Glenn S Gerhard
Journal:  Sci Rep       Date:  2017-03-07       Impact factor: 4.379

8.  The Prevalence of NAFLD and Fibrosis in Bariatric Surgery Patients and the Reliability of Noninvasive Diagnostic Methods.

Authors:  Maurizio Soresi; Daniela Cabibi; Rosaria V Giglio; Stefania Martorana; Giuseppina Guercio; Rossana Porcasi; Antonino Terranova; Luigi A Lazzaro; Maria R Emma; Giuseppa Augello; Melchiorre Cervello; Gianni Pantuso; Giuseppe Montalto; Lydia Giannitrapani
Journal:  Biomed Res Int       Date:  2020-04-26       Impact factor: 3.411

9.  CCL20 is up-regulated in non-alcoholic fatty liver disease fibrosis and is produced by hepatic stellate cells in response to fatty acid loading.

Authors:  Xin Chu; Qunyan Jin; Hui Chen; G Craig Wood; Anthony Petrick; William Strodel; Jon Gabrielsen; Peter Benotti; Tooraj Mirshahi; David J Carey; Christopher D Still; Johanna K DiStefano; Glenn S Gerhard
Journal:  J Transl Med       Date:  2018-04-24       Impact factor: 5.531

Review 10.  Cell-Free Circulating Nucleic Acids as Early Biomarkers for NAFLD and NAFLD-Associated Disorders.

Authors:  Andrey Turchinovich; Ancha Baranova; Oksana Drapkina; Alexander Tonevitsky
Journal:  Front Physiol       Date:  2018-09-20       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.